Meta-analyses of human cell-based cardiac regeneration therapies: What can systematic reviews tell us about cell therapies for ischemic heart disease?

Circulation Research

Volumn 118, Issue 8, 2016, Pages 1264-1272

  Martin Rendon, Enca ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

biomedical research; cell and tissue based therapy; meta analysis; randomized controlled trials as topic; regeneration

Indexed keywords

ARTICLE; CELL REGENERATION; CELL THERAPY; CLINICAL TRIAL (TOPIC); HUMAN; HUMAN CELL BASED CARDIAC REGENERATION THERAPY; ISCHEMIC HEART DISEASE; META ANALYSIS; PRIORITY JOURNAL; QUALITY CONTROL; SYNTHESIS; SYSTEMATIC REVIEW; ANIMAL; BIOLOGICAL THERAPY; LITERATURE; META ANALYSIS (TOPIC); MYOCARDIAL ISCHEMIA; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGENERATION; TRENDS;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; HUMANS; META-ANALYSIS AS TOPIC; MYOCARDIAL ISCHEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGENERATION; REVIEW LITERATURE AS TOPIC;

EID: 84963799288     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.307540     Document Type: Article

References (37)

1. Hartwell D, Colquitt J, Loveman E, Clegg AJ, Brodin H, Waugh N, Royle P, Davidson P, Vale L, MacKenzie L, Clinical effectiveness and cost-effectiveness of immediate angioplasty for acute myocardial infarction: systematic review and economic evaluation. Health Technol Assess 2005 9 1 99, iii-iv
2. Cook C, Cole G, Asaria P, Jabbour R, Francis DP, The annual global economic burden of heart failure. Int J Cardiol 2014 171 368 376. doi: 10.1016/j.ijcard.2013.12.028
3. Keith MC, Bolli R, "String theory" of c-kit(pos) cardiac cells: a new paradigm regarding the nature of these cells that may reconcile apparently discrepant results. Circ Res 2015 116 1216 1230. doi: 10.1161/CIRCRESAHA.116.305557
4. Nowbar AN, Mielewczik M, Karavassilis M, Dehbi HM, Shun-Shin MJ, Jones S, Howard JP, Cole GD, Francis DP, DAMASCENE Writing Group DAMASCENE Writing Group Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. BMJ 2014 348 g2688. doi: 10.1136/bmj.g2688
5. Behfar A, Crespo-Diaz R, Terzic A, Gersh BJ, Cell therapy for cardiac repair-lessons from clinical trials. Nat Rev Cardiol 2014 11 232 246. doi: 10.1038/nrcardio.2014.9
6. Traverse JH, Henry TD, Moye' LA, Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging. Am Heart J 2011 162 671 677. doi: 10.1016/j.ahj.2011.06.019
7. Higgins JPT, Green S, Higgins JPT, Green S, The Cochrane Collaboration The Cochrane Collaboration In: Cochrane Handbook for Systematic Reviews of Interventions 2011 The Cochrane Collaboration
8. Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, Stewart L, The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev 2012 1 2. doi: 10.1186/2046-4053-1-2
9. Jüni P, Egger M, PRISMAtic reporting of systematic reviews and meta-analyses. Lancet 2009 374 1221 1223. doi: 10.1016/S0140-6736(09)61765-7
10. Shea BJ, Bouter LM, Peterson J, Boers M, Andersson N, Ortiz Z, Ramsay T, Bai A, Shukla VK, Grimshaw JM, External validation of a measurement tool to assess systematic reviews (AMSTAR). PLoS One 2007 2 e1350. doi: 10.1371/journal.pone.0001350
11. Peruzzi M, De Falco E, Abbate A, Biondi-Zoccai G, Chimenti I, Lotrionte M, Benedetto U, Delewi R, Marullo AG, Frati G, State of the art on the evidence base in cardiac regenerative therapy: overview of 41 systematic reviews. Biomed Res Int 2015 2015 613782. doi: 10.1155/2015/613782
12. Harvey E, Fisher SA, Doree C, Taggart DP, Martin-Rendon E, Current evidence of the efficacy of cell-based therapies in heart failure. Circ J 2015 79 229 236. doi: 10.1253/circj.CJ-14-1415
13. Afzal MR, Samanta A, Shah ZI, Jeevanantham V, Abdel-Latif A, Zuba-Surma EK, Dawn B, Adult bone marrow cell therapy for ischemic heart disease: evidence and insights from randomized controlled trials. Circ Res 2015 117 558 575. doi: 10.1161/CIRCRESAHA.114.304792
14. Fisher SA, Zhang H, Doree C, Mathur A, Martin-Rendon E, Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2015 9 CD006536. doi: 10.1002/14651858.CD006536.pub4
15. Gyöngyösi M, Wojakowski W, Lemarchand P, ACCRUE Investigators ACCRUE Investigators Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res 2015 116 1346 1360. doi: 10.1161/CIRCRESAHA.116.304346
16. Hristov M, Weber C, The therapeutic potential of progenitor cells in ischemic heart disease-past, present and future. Basic Res Cardiol 2006 101 1 7. doi: 10.1007/s00395-005-0573-0
17. Engblom H, Hedström E, Heiberg E, Wagner GS, Pahlm O, Arheden H, Rapid initial reduction of hyperenhanced myocardium after reperfused first myocardial infarction suggests recovery of the peri-infarction zone: one-year follow-up by MRI. Circ Cardiovasc Imaging 2009 2 47 55. doi: 10.1161/CIRCIMAGING.108.802199
18. Haxhibeqiri-Karabdic I, Hasanovic A, Kabil E, Straus S, Improvement of ejection fraction after coronary artery bypass grafting surgery in patients with impaired left ventricular function. Med Arch 2014 68 332 334. doi: 10.5455/medarh.2014.68.332-334
19. Fisher SA, Brunskill SJ, Doree C, Mathur A, Taggart DP, Martin-Rendon E, Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev 2014 4 CD007888. doi: 10.1002/14651858.CD007888.pub2
20. de Jong R, Houtgraaf JH, Samiei S, Boersma E, Duckers HJ, Intracoronary stem cell infusion after acute myocardial infarction: a meta-analysis and update on clinical trials. Circ Cardiovasc Interv 2014 7 156 167. doi: 10.1161/CIRCINTERVENTIONS.113.001009
21. Fisher SA, Doree C, Mathur A, Martin-Rendon E, Meta-analysis of cell therapy trials for patients with heart failure. Circ Res 2015 116 1361 1377. doi: 10.1161/CIRCRESAHA.116.304386
22. Xu R, Ding S, Zhao Y, Pu J, He B, Autologous transplantation of bone marrow/blood-derived cells for chronic ischemic heart disease: a systematic review and meta-analysis. Can J Cardiol 2014 30 1370 1377. doi: 10.1016/j.cjca.2014.01.013
23. Fisher SA, Doree C, Taggart DP, Mathur A, Martin-Rendon E, Cell therapy for heart disease: trial sequential analyses of two cochrane reviews [Epub ahead of print January 28, 2016]. Clin Pharmacol Ther. doi: 10.1002/cpt.344. http://onlinelibrary.wiley.com/doi/10.1002/cpt.344/abstract;jsessionid=4E635AC3B76068F1AA1E407E1EC54477.f02t03
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG, Measuring inconsistency in meta-analyses. BMJ 2003 327 557 560. doi: 10.1136/bmj.327.7414.557
25. Brunskill SJ, Hyde CJ, Doree CJ, Watt SM, Martin-Rendon E, Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrow-derived cell therapy for ischaemic heart disease. Eur J Heart Fail 2009 11 887 896. doi: 10.1093/eurjhf/hfp101
26. Ang KL, Chin D, Leyva F, Foley P, Kubal C, Chalil S, Srinivasan L, Bernhardt L, Stevens S, Shenje LT, Galiñanes M, Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone. Nat Clin Pract Cardiovasc Med 2008 5 663 670. doi: 10.1038/ncpcardio1321
27. Mozid A, Yeo C, Arnous S, Ako E, Saunders N, Locca D, Brookman P, Archbold RA, Rothman M, Mills P, Agrawal S, Martin J, Mathur A, Safety and feasibility of intramyocardial versus intracoronary delivery of autologous cell therapy in advanced heart failure: the REGENERATE-IHD pilot study. Regen Med 2014 9 269 278. doi: 10.2217/rme.14.3
28. Dalal HM, Doherty P, Taylor RS, Cardiac rehabilitation. BMJ 2015 351 h5000
29. Piepoli MF, Corrà U, Adamopoulos S, Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. Eur J Prev Cardiol 2014 21 664 681. doi: 10.1177/2047487312449597
30. Dalal HM, Wingham J, Lewin R, Doherty P, Taylor RS, Involving primary care and cardiac rehabilitation in a reorganised service could improve outcomes. Heart 2011 97 1191; discussion 1191. doi: 10.1136/heartjnl-2011-300326
31. Rees K, Taylor RS, Singh S, Coats AJ, Ebrahim S, Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev 2004 4 CD003331. doi: 10.1002/14651858.CD003331.pub4
32. Singh S, Loke YK, The safety of rosiglitazone in the treatment of type 2 diabetes. Expert Opin Drug Saf 2008 7 579 585. doi: 10.1517/14740338.7.5.579
33. Singh S, Loke YK, Furberg CD, Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007 298 1189 1195. doi: 10.1001/jama.298.10.1189
34. Yusuf S, Meta-analysis of randomized trials: looking back and looking ahead. Control Clin Trials 1997 18 594 601; discussion 661
35. Yusuf S, Flather M, Magnesium in acute myocardial infarction. BMJ 1995 310 751 752
36. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 1994 343 619 629
37. Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ, Hennekens CH, Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985 6 556 585